Directorio
GSK223559 BEHOLD 2-Ph I/II study: GSK5733584 in combo with anti-cancer therapies for adv solid tumor
This study tests a new cancer medicine. It has 3 parts: - Screening (up to 28 days): You'll get tests like heart checks, scans, and blood work. - Treatment: You'll visit the clinic every 3 weeks to get the study drug. There are different groups testing the drug with other treatments for cancers like ovarian and endometrial. - Follow-Up: After treatment, you'll have check-ups at 30, 60, and 90 days, plus long-term follow-up with more tests.
Completing an 8 question survey
We are doing this study to understand how hand transplantation can help you with your daily activities compared to before the transplant.
We are doing this study to better understand how HIV affects the body.
The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.
We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).